Skip Navigation


Annals of Oncology Advance Access originally published online on October 26, 2008
Annals of Oncology 2008 19(12):2089-2090; doi:10.1093/annonc/mdn645
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
19/12/2089    most recent
mdn645v2
mdn645v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Akiyama, Y.
Right arrow Articles by Sasaki, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Akiyama, Y.
Right arrow Articles by Sasaki, Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

letters to the editor

Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy

The first 10% of the full text of this article appears below.

Polymorphisms of the UDP-glucuronosyltransferase (UGT) 1A1 gene, such as UGT1A1*28 and UGT1A1*6, can cause severe neutropenia and diarrhea in patients who receive irinotecan [1, 2]. Homozygosity for UGT1A1*28 is associated with less efficient glucuronidation of SN-38, the active metabolite of irinotecan, resulting in increased plasma SN-38 concentrations. Four pharmacogenetic trials have demonstrated an association between UGT1A1*28 genotype and irinotecan-induced hematologic . . . [Full Text of this Article]

funding

Y. Akiyama1,2, K. Fujita1,2, F. Nagashima1,2, W. Yamamoto1, H. Endo1, Y. Sunakawa1, K. Yamashita1, H. Ishida1, K. Mizuno1, K. Araki1, W. Ichikawa1, T. Miya1, M. Narabayashi1, K. Kawara1, M. Sugiyama1, T. Hirose1, Y. Ando1 and Y. Sasaki1,2,*

1 Department of Medical Oncology, Saitama International Medical Center-Comprehensive Cancer Center, Saitama Medical University
2 Project Research Laboratory, Research Center for Genomic Medicine, Saitama Medical University, Saitama, Japan

* (E-mail ysasaki@saitama-med.ac.jp)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?